Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ZIVO Bioscience, Inc. (ZIVO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, annual and quarterly reports and other documents filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with a Commission File Number of 000-30415, ZIVO uses these filings to report material events, describe its business and update investors on governance and financial matters.
For a research and development company like ZIVO, SEC filings are a key source of information on its biotech and agtech activities involving proprietary algal and bacterial strains, biologically active molecules and complexes, and related intellectual property. Filings can explain how the company characterizes its focus on human and animal health applications, outline risk factors and summarize relationships with collaborators and counterparties.
Current reports on Form 8-K, such as the filing describing the resignation of a Chief Financial Officer and the appointment of an Interim Chief Financial Officer under an independent contractor services agreement, document significant management changes and associated compensation arrangements. Investors can also use this page to monitor future 10-K annual reports and 10-Q quarterly reports for updates on ZIVO’s R&D programs, liquidity, and any disclosed licensing or collaboration agreements.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in plain language, helping readers quickly understand lengthy documents. Real-time updates from EDGAR ensure that new ZIVO filings appear promptly, while access to ownership and insider transaction reports, such as Form 4 when filed, allows users to track equity-related activity by directors and officers. This combination of raw filings and AI analysis offers a structured way to review ZIVO’s regulatory history and ongoing disclosure record.
Strome-affiliated investors updated their ownership in Zivo Bioscience’s common stock. Mark E. Strome now reports beneficial ownership of 472,942 shares, or 12.10% of the company’s 3,888,595 shares outstanding as of November 9, 2025.
Strome Mezzanine Fund II holds 266,198 shares, representing 6.81% of the company, after merging with Strome Mezzanine Fund on December 31, 2025 and becoming the surviving entity. SMF ceased to hold any shares following this merger.
On February 12, 2026, Strome Mezzanine Fund II acquired 20,000 shares of Zivo Bioscience at $9.77 per share under a Securities Purchase Agreement and received a warrant, for no additional consideration, exercisable for 2,000 additional shares at $9.77 per share, subject to adjustments.
Zivo Bioscience reported that investment entities associated with 10% owner Mark E. Strome, through Strome Mezzanine Fund II, LP, bought 20,000 shares of common stock at $9.77 per share and 2,000 common stock purchase warrants on February 12, 2026.
After these indirect purchases, the entities reported beneficial ownership of 472,942 common shares and 45,071 warrants.
Zivo Bioscience insider reporting shows an indirect open-market purchase of common stock tied to director and 10% owner Laith L. Yaldoo. On 02/10/2026, HEP Investments LLC, an entity associated with Yaldoo, bought 2,434 shares of Zivo Bioscience common stock at $10.27 per share. Following this transaction, HEP Investments LLC indirectly held 582,072 shares of common stock.
Zivo Bioscience director Alison Cornell reported buying additional company stock. On January 26, 2026, she purchased 11,709 shares of common stock at a price of $8.54 per share. Following this transaction, she directly beneficially owns 279,481 shares of Zivo Bioscience common stock.
Zivo Bioscience, Inc. President and CEO John B. Payne reported an open-market purchase of company stock. On 01/26/2026, he bought 11,709 shares of common stock at $8.54 per share. Following this transaction, he directly owns 19,618 shares of Zivo Bioscience common stock.
Zivo Bioscience director and 10% owner Christopher D. Maggiore reported a small open-market purchase of common stock. On 01/14/2026, he bought 1,766 shares of Zivo Bioscience common stock at a price of $8.49 per share, coded as a purchase transaction.
Following this trade, Maggiore beneficially owned 519,292 shares of Zivo Bioscience common stock in direct ownership form, indicating his stake as both a director and a more than 10% shareholder.
Zivo Bioscience director and 10% owner–associated entity acquires additional shares. On January 14, 2026, an entity associated with Laith L. Yaldoo, HEP Investments LLC, purchased 1,766 shares of Zivo Bioscience common stock at $8.49 per share in an open-market transaction.
Following this purchase, HEP Investments LLC indirectly holds 579,638 shares of Zivo Bioscience common stock attributed to Yaldoo’s beneficial ownership.
Zivo Bioscience, Inc. reported insider information for its Chief Financial Officer, William A. Sullivan, in a Form 3 initial ownership filing. The filing shows that as of the event date of 12/19/2025, he reported beneficial ownership of 0 shares of Zivo Bioscience, Inc. common stock and no derivative securities such as options or warrants. The form is filed as an individual reporting person and confirms that he currently holds no direct or indirect equity or derivative position in the company.
Zivo Bioscience, Inc. reported that Chief Financial Officer Keith R. Marchiando has resigned from his CFO role effective immediately and will end his employment on December 31, 2025. Under a separation and release agreement, he will continue to receive his current salary of $27,040 per month through December 31, 2026, and will retain an option to acquire 150,000 shares of common stock at an exercise price of $7.96 per share, exercisable until June 30, 2027.
The company appointed William A. Sullivan as Interim Chief Financial Officer effective December 19, 2026, under an independent contractor services agreement. He will be paid $285.00 per hour for his work, with an initial 60-day term that automatically renews for one-month periods unless either party provides notice. Mr. Sullivan is subject to confidentiality and post-termination restrictions aimed at protecting the company’s business relationships.
Zivo Bioscience, Inc. director and 10% owner reported buying additional company shares. On 11/28/2025, an indirect account, HEP Investments LLC, purchased 2,777 shares of Zivo Bioscience common stock at a price of $9 per share. After this transaction, the reporting person beneficially owned 577,872 shares of common stock indirectly through HEP Investments LLC.